Stimulatory regulators for DNA methyltransferase activity, such as Dnmt3L and some Dnmt3b isoforms, affect DNA methylation patterns, thereby maintaining gene body methylation and maternal methylation imprinting, as well as the methylation landscape of pluripotent cells. Here we show that metastasis-related methyltransferase 1 (Merm1), a protein deleted in individuals with Williams-Beuren syndrome, acts as a repressive regulator of Dnmt3a. Merm1 interacts with Dnmt3a and represses its methyltransferase activity with the requirement of the binding motif for S-adenosyl-L-methionine. Functional analysis of gene regulation revealed that Merm1 is capable of maintaining hypomethylated rRNA gene bodies and co-localizes with RNA polymerase I in the nucleolus. Dnmt3a recruits Merm1, and in return, Merm1 ensures the binding of Dnmt3a to hypomethylated gene bodies. Such interplay between Dnmt3a and Merm1 facilitates transcriptional elongation by RNA polymerase I. Our findings reveal a repressive factor for Dnmt3a and uncover a molecular mechanism underlying transcriptional elongation of rRNA genes.
Introduction
Methylation of cytosine bases at CpG dinucleotide is an important regulatory modification in eukaryotic genomes. Three catalytically active DNA methyltransferases (Dnmts), Dnmt1, Dnmt3a, and Dnmt3b, have been identified in mammals (Bestor et al., 1988; Yen et al., 1992; Okano et al., 1998; Xie et al., 1999) . Dnmt1 functions predominantly in maintaining DNA methylation patterns (Gruenbaum et al., 1982; Leonhardt et al., 1992) , while Dnmt3a and Dnmt3b are responsible for de novo methylation of unmethylated and hemimethylated DNA (Hsieh, 1999; Okano et al., 1999) . Several members of the Dnmt3 family, including DNA methyltransferase 3-like protein Dnmt3L and Dnmt3b isoforms without sequence motifs necessary for methyltransferase activity, have been shown to act as stimulatory factors to facilitate DNA methyltransferase activity (Chédin et al., 2002; Suetake et al., 2004; Duymich et al., 2016) . Dnmt3L has been identified as a regulatory protein of Dnmt3a and Dnmt3b that stimulates de novo methylation, thereby maintaining gene body methylation, maternal methylation imprinting, and the methylation landscape of pluripotent cells (Bourc'his et al., 2001; Neri et al., 2013) . Removal of Dnmt3L prevents methylation of sequences that are normally maternally methylated and causes developmental defects in mouse embryos (Bourc'his et al., 2001) . Catalytically inactive Dnmt3b isoforms are able to collaborate with Dnmt3a to restore DNA methylation, especially in gene bodies in differentiated cells (Duymich et al., 2016) . In addition, Uhrf1 has been recognized as a Dnmt1 accessory protein that binds to hemimethylated CpG and recruits Dnmt1 to ensure the DNA methylation pattern during DNA replication or repression of its direct target genes (Bostick et al., 2007; Sharif et al., 2007) . Regulatory proteins for DNA methyltransferases play critical roles in controlling DNA methylation and gene expression patterns, and identification of new regulatory proteins for both stimulatory and repressive regulators of DNA methyltransferases will provide further insight into mechanisms of gene expression and mammalian development, as well as human disease.
Metastasis-related methyltransferase 1 (Merm1) was originally identified as Wbscr22. It is one of 26-28 genes that are deleted from 7q11.23 in Williams-Beuren syndrome, which is characterized by distinctive facial features, mental retardation, hypercalcemia, and hypertension (Doll and Grzeschik, 2001) . Merm1 is conserved in yeast and human. This gene encodes a protein containing a nuclear localization signal and an S-adenosyl-L-methionine (SAM) binding motif typical of methyltransferases. Initially, Merm1 was shown to be implicated in methylation and processing of 18S rRNA, and its stability was found to be regulated by TRMT112 through the ubiquitin-proteasome pathway (Figaro et al., 2012; Õ unap et al., 2013; Tafforeau et al., 2013; Haag et al., 2015; Õ unap et al., 2015; Zorbas et al., 2015) . Further investigation revealed that Merm1 plays a critical role in epigenetic regulation of gene expression in mammals. Merm1 regulates glucocorticoid receptor recruitment to the genome and mediates subsequent histone modification to maintain open chromatin (Jangani et al., 2014) , suggesting that it plays a role in chromatin-based gene expression. In addition, Merm1 promotes cancer metastasis by inhibiting Zac1-mediated p53-dependent apoptosis, in which Merm1 methylates histone H3 lysine 9 (H3K9) at the Zac1 locus, thereby producing a transcriptionally repressive chromatin environment (Nakazawa et al., 2011) . Thus, Merm1 is able to drive epigenetic alterations to affect gene activities. Merm1 itself does not have active histone or DNA methyltransferase activities (Nakazawa et al., 2011) ; therefore, its role in gene expression may be to function as a recruiter or modulator for epigenetic enzymes.
Here we report for the first time that Merm1 acts as a repressive regulator of Dnmt3a and participates in regulating gene body methylation and RNA polymerase I (Pol I) transcription elongation at rRNA genes. We found that Dnmt3a binds to unmethylated rDNA gene bodies because of inhibition of its DNA methyltransferase activity by Merm1. Through direct binding to Dnmt3a, Merm1 maintains gene body hypomethylation, leading to co-occupancy with Dnmt3a, Pol I, and upstream binding factor (UBF) at unmethylated gene bodies. This complex is capable of ensuring efficient Pol I elongation on rDNA templates. Thus, Merm1 is a repressive regulator of Dnmt3a that participates in generating unmethylated gene bodies that allow transcriptional elongation by Pol I.
Results

Merm1 interacts with Dnmt3a and inhibits its DNA methyltransferase activity
To assess the biological functions of Merm1, co-immunoprecipitation was performed to explore its binding partners. Surprisingly, Dnmt3a and Merm1 immunoprecipitated each other in vivo ( Figure 1A) . Furthermore, co-immunoprecipitation assays utilizing nuclear extracts from 293T cells harboring ectopic co-expression of HA-tagged Merm1 and Myc-tagged Dnmts confirmed that Merm1 precipitated Dnmt3a and Dnmt3b ( Figure 1B) . To assess the physical interaction between these two proteins, recombinant GST-tagged human Merm1 and Dnmts were prokaryotically purified and subjected to pull-down assays. Merm1 interacted directly with Dnmt3a and Dnmt3b, but not Dnmt1 ( Figure 1C) . These results demonstrated that Merm1 interacts directly with Dnmt3a and Dnmt3b.
Bioinformatic sequence alignments showed that Merm1 contains several domains (I, IV, IX, and X) that are conserved in canonical Dnmts such as Dnmt1, Dnmt3a, and Dnmt3b (Supplementary Figure S1A) . Similar to Dnmt3L, Merm1 does not contain a complete set of canonical DNA methyltransferase domains, and knockdown of Merm1 did not affect histone modification levels, indicating that it is not a histone or DNA methyltransferase enzyme (Supplementary Figures S1B and S2) . Given that Merm1 interacts with Dnmt3a and Dnmt3b, we reasoned that it may be involved in modulating the DNA methyltransferase activity of known Dnmts. The regulatory effects of Merm1 on the activity levels of DNA methyltransferase Dnmt3a and Dnmt3b were assessed via the 3 Hlabeled S-adenosyl methionine (SAM) addition method in vitro. The liquid scintillation analyzer results revealed that Merm1 inhibited the methyltransferase activity of Dnmt3a without affecting that of Dnmt3b, although Merm1 and Dnmt3b were capable of direct interaction ( Figure 1D and Supplementary Figure S3 ).
Merm1 has a critical methyltransferase-related domain in its N-terminal and C-terminal regions. The N-terminal domain possesses a conserved motif (motif I) that consists of four glycines (4G), which are predicted to be responsible for binding of the methyl group donor SAM and cofactors ( Figure 1E and Supplementary Figure S1A ) (Nakazawa et al., 2011) . To determine which domain of Merm1 is essential for its interaction with Dnmt3a and inhibitory effect on Dnmt3a activity, two truncation mutants (Merm1-N and Merm1-C) of HA-tagged Merm1 were generated and transiently overexpressed in 293T cells. The Merm1-N mutant was efficiently pulled down by the purified GST-Dnmt3a fusion protein, whereas relatively less of the Merm1-C mutant was precipitated by Dnmt3a ( Figure 1F) . Similarly, immunoprecipitation analysis using specific Dnmt3a antibodies showed that the Merm1-N mutant co-precipitated Dnmt3a with higher affinity than that with which it co-precipitated the Merm1-C mutant ( Figure 1G ). These results suggest that Merm1-N is required for the interaction between Merm1 and Dnmt3a. Considering that Merm1-N contains the SAM binding motif of Merm1, we constructed a substitution mutant (Merm1-4G4R*) with a disrupted SAM binding motif structure, which impaired SAM binding (Nakazawa et al., 2011) , to test whether this motif contributed to the interaction between Merm1 and Dnmt3a. Co-immunoprecipitation analysis with Myc-tagged Dnmt3a, HAtagged Merm1, or the 4G4R* mutant showed that the 4G4R* mutant significantly weakened the interaction between Merm1 and Dnmt3a ( Figure 1H ). Consistent with this finding, the inhibitory effect of Merm1 on the methyltransferase activity of Dnmt3a was mildly alleviated in the HA-Merm1-4G4R* substitution mutant and severely disrupted in the HA-Merm1-N truncation mutant ( Figure 1H) . Notably, although the C-terminal domain was not indispensable in the binding of Merm1 to Dnmt3a, it was In vitro DNA methyltransferase activity assays were performed using purified proteins and synthetic substrate DNA. Error bars represent SD (n = 3). (E) Schematic illustration of the HA-tagged full-length (HA-Merm1), four glycines (4 G) to four arginines (4 R) substitution mutation (HA-Merm1-4G-4R*), N-terminal domain (HA-Merm1-N), and C-terminal domain (HA-Merm1-C) truncation mutants of Merm1. The numbers are the amino acid sequence numbers of Merm1. I, IV, IX, and X are conserved motifs of AdoMet-MTases. NLS, nuclear localization signal. (F) The N-terminal domain of Merm1 interacts with Dnmt3a in vitro. Whole-cell extracts from 293T cells expressing either the HA-tagged N-terminal domain or C-terminal domain of Merm1 were incubated with immobilized GST-Dnmt3a fusion proteins. Bound proteins were analyzed by immunoblotting using an anti-HA antibody. (G) The N-terminal domain of Merm1 binds to Dnmt3a. Whole-cell extracts from 293T cells expressing either the HA-tagged N-terminal domain or C-terminal domain of Merm1 were incubated with an antibody against Dnmt3a. Co-precipitated proteins were monitored by immunoblotting using an anti-HA antibody. (H) Mutation of the predicted SAM binding motif weakens the interaction between Merm1 and Dnmt3a. Nuclear extracts from 293T cells expressing HA-Merm1-4G-4R* and Myc-Dnmt3a were incubated with antibodies against HA or Myc. Co-precipitated proteins were monitored by immunoblotting. (I) Both the N-terminal and C-terminal domains of Merm1 are required for efficient inhibition of the methyltransferase activity of Dnmt3a. Whole-cell extracts from 293T cells expressing the indicated HA-tagged proteins were used to perform DNA methyltransferase activity assays. *P < 0.1, **P < 0.01, ***P < 0.001, two-tailed unpaired Student's t-tests were performed. required for efficient repression of the methyltransferase activity of Dnmt3a ( Figure 1I ), suggesting that the integrity of Merm1 is a prerequisite for its inhibitory effect on Dnmt3a. Taken together, these findings suggest that Merm1 interacts with Dnmt3a and inhibits its DNA methyltransferase activity in a manner requiring the SAM binding motif at the N-terminus of Merm1.
Merm1 is capable of maintaining hypomethylated rDNA gene bodies Next, we tested whether the regulatory effect of Merm1 on Dnmt3a is involved in regulating gene expression. Previously, both Merm1 and Dnmt3a have been shown to localize in the nucleolus, and Dnmt3a has been shown to associate directly with rDNA (Majumder et al., 2006) . Therefore, we assessed whether Dnmt3a and Merm1 function together to regulate the epigenetic state of rDNA and thereby regulate rDNA transcription. To monitor the binding of Merm1 to rDNA, we performed chromatin immunoprecipitation (ChIP) assays comparing Merm1 occupancy with that of Pol I. Merm1 binding was observed throughout the rDNA repeats, but it was enriched at rDNA gene bodies ( Figure 2A) . Although the overall level of rDNA-associated Merm1 was lower than that of Pol I, it was much higher than that of IgG (Supplementary Figure S4) . In addition, association of Merm1 with gene bodies was significantly inhibited due to decreased expression of Merm1 caused by deleting one allele of Merm1 (designated as Merm1
) via CRISPR/Cas9 genome editing ( Figure 2B ), underscoring the specificity of the ChIP assays. Of note, we were unable to obtain homozygous deletion of Merm1 (Merm1
) in cells or mice, likely because of lethal effects caused by the complete loss of Merm1. Consistent with this finding, RNAi-mediated knockdown of the Merm1 ortholog in Caenorhabditis elegans was embryonic-lethal (Piano et al., 2002) .
Given that Merm1 was enriched at gene bodies, its regulatory role on epigenetic modifications on gene bodies was assessed. Merm1 affected rDNA gene body methylation in wild-type and Merm1 +/− cells. Bisulfite sequencing analysis showed extensive gene body methylation at rDNA gene bodies, and depletion of Merm1 significantly increased the proportion of methylated gene bodies from 43% to 78% ( Figure 2C and D). To verify that Merm1 regulates gene body methylation, methylated DNA immunoprecipitation sequencing (MeDIP-seq) assays were performed. Knockdown of Merm1 increased the level of gene body methylation, but DNA methylation at intergenic spacers (IGS) remained unchanged ( Figure 2E ), which confirmed the validity of the MeDIP-seq assay. These results indicate that Merm1 maintains hypomethylated rRNA gene bodies.
Merm1 is recruited by Dnmt3a and ensures the binding of Dnmt3a to hypomethylated gene bodies via co-occupation with Pol I and UBF
The finding that Merm1 inhibits the activity of Dnmt3a and maintains hypomethylated rDNA gene bodies raises the possibility that both Dnmt3a and Merm1 bind to hypomethylated gene bodies. Indeed, the ChIP-bisulfite assays revealed that Merm1 was associated exclusively with unmethylated gene bodies, whereas Dnmt1 was only associated with hypermethylated rDNA, and Pol I and UBF bound to unmethylated rDNA as expected ( Figure 3A and B). However, Dnmt3a bound to both methylated and unmethylated gene bodies, but was preferentially associated with the latter ( Figure 3C ). Thus, Pol I, Merm1, and Dnmt3a are all restricted to unmethylated gene bodies, suggesting the possibility that these proteins may co-occupy gene bodies. SequentialChIP assays confirmed that Merm1 co-occupied with Dnmt3a, Pol I, and UBF, but not with Dnmt1 ( Figure 3D ), suggesting the cooccupancy on hypomethylated rDNA gene bodies coordinates rDNA transcription elongation.
Significantly, ChIP-bisulfite assays carried out in Merm1
+/− cells revealed that upon depletion of Merm1, Dnmt3a was no longer bound to hypomethylated rDNA gene bodies, but rather was exclusively associated with hypermethylated rDNA gene bodies. However, the association between Pol I and hypomethylated gene bodies was unchanged in Merm1 +/− cells ( Figure 3E and F; Supplementary Figure S5 ). These results suggest that association of Dnmt3a with hypomethylated rDNA gene bodies was caused by the repressive effect of Merm1 on Dnmt3a, because depletion of Merm1 relieved this inhibitory effect and allowed Dnmt3a to bind to hypermethylated gene bodies. Moreover, neither loss of Dnmt3a nor concurrent disruption of Merm1 and Dnmt3a (Merm1
, also denoted as DKO) decreased gene body methylation (Supplementary Figure S6) , indicating that depletion of Dnmt3a leads to disassociation of the Merm1−Dnmt3a complex and departure of Merm1 from gene bodies. Indeed, depletion of Dnmt3a impaired the association between Merm1 and rDNA ( Figure 3G ), whereas knockdown of Merm1 enhanced the binding of Dnmt3a to rDNA ( Figure 3H ), suggesting that Dnmt3a guides Merm1 to rDNA gene bodies. Taken together, these findings demonstrate that Merm1 is recruited by Dnmt3a, thereby establishing hypomethylated gene bodies where Dnmt3a, Pol I, and UBF show co-occupancy.
Merm1 co-localizes with Pol I and UBF
Given that Merm1, UBF, and Pol I bind to and co-occupy unmethylated gene bodies, we assumed that Merm1 may interact and co-localize with Pol I and UBF. Indeed, we found that Merm1 interacted with RNA Pol I and UBF, but not with productive preinitiation complex components TAFI95 and TIF-IA, which are restricted to rDNA promoters ( Figure 4A ). To further assess the interactions among Merm1, Pol I, and UBF, we investigated the sub-cellular localization of Merm1 using indirect immunofluorescence microscopy. Immunofluorescent staining of Merm1 with a commercial antibody showed that endogenous Merm1 was observed throughout the nucleus in 293T cells, with a portion co-localized with Pol I and UBF (Supplementary Figure S7A) . Furthermore, Merm1 fusion proteins with an HA or GFP tag were generated and transiently transfected into 293T, U2OS, and NIH3T3 cells. The fluorescent signals were captured using a spinning-disk confocal laser scanning microscope or an inverted immunofluorescent microscope, after which the signals were analyzed. HAtagged Merm1 was most pronounced in the nucleoli of 293T cells, where it partially co-localized with Pol I and UBF (Supplementary Figure S7B) . The GFP-tagged Merm1 signal was also enriched in the nucleoli of 293T and NIH3T3 cells, where it partially co-localized with Pol I and UBF (Supplementary Figure S7C and D) . Moreover, analysis of the fluorescent signals derived from 3D stacks of GFP-tagged Merm1 at different angles confirmed that Merm1 was associated with Pol I and UBF in U2OS cells (Figure 4B and C; Supplementary Movies S1 and S2). Taken together, these results confirm that Merm1 interacts and colocalizes with Pol I and UBF. Interplay between Merm1 and Dnmt3a facilitates Pol I elongation The finding that Merm1 is enriched at gene bodies and interacts with Pol I and UBF, but not with promoter preinitiation complex components, suggests that the interplay between Dnmt3a and Merm1 may regulate rDNA transcription elongation. Therefore, the level of pre-rRNA synthesis in Merm1 Figure S8) . Short 5′-fluorouridine (FUrd) pulse-labeling of DKO cells revealed drastic decreases in the rates of rRNA synthesis and proliferation ( Figure 5A and B),
suggesting that interaction between Dnmt3a and Merm1 facilitated rDNA transcription. However, examination of the occupancy of Pol I at rDNA in the wild-type and DKO cells using ChIP assays produced the unexpected result that, in contrast with compromised pre-rRNA synthesis, simultaneous loss of Merm1 and Dnmt3a led to increased occupancy of Pol I at gene bodies ( Figure 5C ). Wholegenome scale ChIP-seq analysis of Pol I confirmed that concurrent depletion of Merm1 and Dnmt3a increased Pol I enrichment at rDNA gene bodies ( Figure 5D ). These findings suggested that the severe inhibition of transcription by DKO cells may be caused by retardation of Pol I elongation and accumulation at gene bodies. To test this hypothesis, an actinomycin D (AMD) release assay was 
/Dnmt3a
−/− cells (DKO #1 and DKO #2) were treated with 0.05 μg/ml AMD for 1 h, followed by replacement of the medium with AMD-free medium to allow transcription for 8, 16, or 24 h. Groups that were not subjected to AMD treatment (No AMD) or subjected to 1 h of AMD treatment (AMD 1 h) were used as controls. (F) The AMD release assay shows that simultaneous depletion of Merm1 and Dnmt3a reduces the transcription elongation rate of Pol I. ChIP assays were performed using primers that amplify the 28S rRNA coding region to show the relative rDNA occupancy of Pol I in the indicated treated cells. Error bars represent SD (n = 3). *P < 0.1, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed unpaired Student's t-tests were performed.
performed to compare Pol I elongation in wild-type and DKO cells. Cells were treated with a low concentration of AMD for 1 h to stop rDNA transcription and trap Pol I at rDNA promoters, after which the medium containing AMD was replaced with new medium without AMD to reinitialize movement of Pol I from promoters to gene bodies ( Figure 5E ). Following the AMD treatment and reinitialization of Pol I movement, Pol I enrichment at rDNA gene bodies was tested. AMD significantly decreased enrichment of Pol I at rDNA gene bodies, but gradual re-occupancy of Pol I at rDNA gene bodies was observed in 293T and DKO cells following the removal of medium containing AMD ( Figure 5F ). However, DKO cells exhibited a much slower re-occupancy rate of Pol I at rDNA gene bodies in comparison with that of wild-type cells ( Figure 5F ), suggesting that simultaneous deletion of Merm1 and Dnmt3a led to retardation of Pol I movement along gene bodies. Taken together, these findings demonstrate that Merm1 and Dnmt3a synergistically facilitate rDNA transcription by supporting Pol I elongation at rDNA gene bodies.
Discussion
Over the past few decades, numerous studies have focused on elucidating the mechanisms underlying DNA methylation and the manner in which it controls gene transcription. With regard to rRNA genes, Dnmt1, Dnmt3a, and Dnmt3b have been shown to localize in the nucleolus and associate with rDNA, implying that they have essential roles in epigenetic control of rDNA transcription (Majumder et al., 2006) . It is widely acknowledged that DNA methylation in promoters silences rRNA genes, while active promoters are characterized by DNA hypomethylation (Grummt and Längst, 2013) . Dnmt1-and/or Dnmt3b-mediated DNA methylation on rDNA promoters can impair the assembly of the transcription initiation complex, including recruitment of Pol I and UBF (McStay and Grummt, 2008) . In contrast, genetic disruption of Dnmt1 and Dnmt3b leads to hypomethylation and activation of rDNA promoters (Majumder et al., 2006; Gagnon-Kugler et al., 2009; Grummt and Längst, 2013) . However, neither ectopic Dnmt3a nor decreased expression of Dnmt3a affected rDNA promoter activity (Majumder et al., 2006) , indicating that Dnmt3a plays a role distinct from those of Dnmt1 and Dnmt3b. Indeed, unlike Dnmt1 or Dnmt3b, Dnmt3a is not required for the maintenance of methylation at heterochromatic repeat regions . Deletion of Dnmt1 or Dnmt3b leads to early embryonic lethality, while Dnmt3a-null mice appeared to be grossly normal at birth, but showed postnatal developmental defects and died prematurely, suggesting that Dnmt3a regulates euchromatic expression and postnatal development (Li et al., 1992) . More importantly, Dnmt3a has been found to occupy the gene bodies of a large cohort of neurogenic genes, for which it facilitates transcription by functionally antagonizing polycomb repression. These findings reveal that Dnmt3a may maintain active transcription elongation of genes critical for development (Wu et al., 2010) . In this study, we revealed that Dnmt3a is involved in the modulation of gene body methylation and transcription elongation of rRNA genes. Thus, our results and others demonstrate Dnmt3a-dependent transcription elongation of Pol I-and Pol II-transcribed genes.
In addition, our study identified a repressive regulator of Dnmt3a, nucleolar protein Merm1, which cooperated with Dnmt3a to modulate the methylation status of gene bodies, thereby regulating their capacity for rDNA transcription elongation. Several regulators have been shown to enhance the activity of DNA methyltransferases and play critical roles in maintaining DNA methylation patterns (Ché din et al., 2002; Duymich et al., 2016) . Our results reveal that Merm1 acts as a negative regulator of Dnmt3a. Although Merm1 contains a SAM binding motif, it does not possess DNA methyltransferase activity or the conserved catalytic domain common to DNA methyltransferases. Remarkably, Merm1 negatively regulates the DNA methyltransferase activity of Dnmt3a to generate unmethylated rDNA templates, thereby allowing Pol I transcription elongation. Inhibition of methyltransferase activity by Merm1 resulted in association of Dnmt3a with unmethylated gene bodies. Under these circumstances, Dnmt3a could not exert its rDNA methyltransferase activity, and Dnmt3a knockout did not further affect gene body methylation. However, loss of Merm1 restored the DNA methyltransferase activity of Dnmt3a and rendered Dnmt3a able to methylate rDNA gene bodies, thus enhancing rDNA gene body methylation. Our findings provide new insight into the manner in which Dnmt3a and Merm1 interact to modulate the methylation state of gene bodies and control gene transcription elongation.
Previously, Merm1 and its yeast homolog Bud23 were identified as 18S rRNA base methyltransferases that play critical roles in pre-rRNA processing (Figaro et al., 2012; Õ unap et al., 2013; Tafforeau et al., 2013; Létoquart et al., 2014; Haag et al., 2015; Õ unap et al., 2015; Zorbas et al., 2015) . It is clear that Merm1 regulates pre-rRNA processing, but it may have additional functions in mammalian cells. First, although mammalian Merm1 can facilitate rRNA methylation, such modification does not seem to be required for pre-processing (Zorbas et al., 2015) . Furthermore, human Merm1 and Bud23 have only 47% amino acid similarity. Moreover, yeast does not possess cytosine DNA methyltransferases, so yeast DNA is unmethylated. These findings suggest that human Merm1 and Bud23 have similar, but probably not identical functions (Nakazawa et al., 2011; Jangani et al., 2014; Õ unap et al., 2015) . Indeed, Merm1 has been shown to drive alterations of epigenetic modification at promoters in mammalian cells (Jangani et al., 2014) , and here we verified that Merm1 acts as a repressive regulator of Dnmt3a and activates rDNA transcription. Thus, in addition to its role in pre-rRNA processing, modulation of epigenetic states by Merm1 is required for rDNA transcription. It is not surprising that Merm1 plays dual roles in the processes of rDNA transcription and pre-rRNA processing. Some other proteins, such as Dnmt1, nucleolin, and fibrillarin, have well-characterized roles in multiple steps of rRNA processing, including regulation of rDNA transcription, pre-rRNA splicing, and assembly of ribosomal particles (Egyhazi et al., 1988; Grummt, 1998; Roger et al., 2002) . With regard to Dnmt1, the extensive loss of DNA methylation at rDNA loci caused by Dnmt1 knockout reduced rDNA transcription and led to defective rRNA processing (Gagnon-Kugler et al., 2009) , suggesting that the ribosomal synthesis rate is controlled by regulating the rates of transcription and subsequent rRNA maturation.
In conclusion, we have shown that Merm1 interacts with Pol I and UBF and regulates the activity of Dnmt3a, thereby collaborating to control rDNA transcription elongation. Depletion of Merm1 increased gene body methylation and consequently decreased Pol I binding. Simultaneous knockout of one allele of Merm1 and two alleles of Dnmt3a did not affect gene body methylation, but rather retarded Pol I elongation, resulting in the accumulation of Pol I on rDNA templates. This finding suggests that both Merm1 and Dnmt3a are required for transcriptional elongation of rDNA ( Figure 6 ). In addition, depletion of either Merm1 or Dnmt3a produced similar changes in the expression levels of many Pol IItranscribed genes (Supplementary Figure S9) , suggesting that Merm1 and Dnmt3a cooperate to regulate Pol I-and Pol II-mediated gene transcription. Therefore, our results may reveal a general cellular mechanism, in which the generation of unmethylated gene bodies by a repressive regulator of DNA methyltransferases allows transcription elongation. There are alternative pathways that lead to gene bodies demethylation, such as that involving the TET family of demethylases (Santi et al., 1983; He et al., 2011) . Therefore, it is essential to explore the functional relationships between TET proteins, Merm1, and Dnmt3a to reveal how they may cooperate to control gene body methylation and transcriptional elongation.
Materials and methods
Cell culture
U2OS, NIH3T3, 293T, and the derived knockout or knockdown cells were all cultured at 5% CO 2 , 37°C in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS). For growth curve, wild-type 293T and knockout cells were in inoculums of 1 × 10 6 , and NIH3T3 and the corresponding knockdown cells were in inoculums of 0.5 × 10 6 in 100-mm culture dish. Cells were counted with hemocytometer every day and cumulative cell numbers were calculated and presented.
Plasmids cDNA encoding human Merm1 (GenBank accession number NM_017528) was PCR amplified with specific primers and the amplicons were ligated into pEGFP-C1, pGEX-4T-1, and pCMV-3 × HA to generate recombinant expression constructs. cDNA encoding mouse Merm1 (GenBank accession number NM_025375.3) was cloned into pEGFP-C1. Transcript variants of Merm1 to produce Merm1-4G4R, Merm1-N, and Merm1-C were cloned and inserted into pCMV-3 × HA to generate recombinant expression vectors. The primers used to generate recombinant constructs are listed in Supplementary Table S1 . pcDNA3/Myc-Dnmt1 (Addgene plasmid # 36939), pcDNA3/Myc-Dnmt3a (Addgene plasmid # 35521), and pcDNA3/Myc-Dnmt3b1 (Addgene plasmid # 35522) are gifts from Arthur Riggs (Chen et al., 2005; Li et al., 2006) .
Antibodies
Anti-Dnmt3a (sc-20703), anti-Merm1 (sc-135322), anti-RPA194 (sc-28714), anti-UBF (sc-9131X), and anti-c-Myc (sc-40X) were purchased from Santa Cruz. Anti-α-tubulin (T6199), anti-HA (H9658), and anti-Bromodeoxyuridine (B2531) were obtained from Sigma. Anti-5-methylcytosine (BI-MECY-0100) was from Eurogentec. AntiH3K4me3 (04-745) and anti-H3K27me3 (07-449) were from Upstate. Anti-Merm1 (ab97911), anti-H3K9me3 (ab8898), anti-H3K36me3 (ab9050), anti-H4K20me3 (ab9053), and anti-H3 (ab1791) were from Abcam. Secondary antibodies IRDye800CW goat antimouse IgG (926-32210) and IRDye800CW goat anti-rabbit IgG (926-32211) were purchased from LI-COR.
Targeting strategy of knockdown and knockout
For knockdown in NIH3T3 cells, the shRNA targeting mouse Merm1 (5′-TCGCAACTCACGGATGATT-3′) was cloned into the retroviral vector pQXCIP. Plat-E cell was transfected with the recombinant pQXCIP constructs to package the retrovirus. The packaged virus was collected and applied to infect NIH3T3 cells. Cells were selected with puromycin for 5 days. For knockout in 293T cells, the CRISPR/Cas9 system was utilized. Recombinant pcDNA3.1-NLSCas9-NLS containing human Cas9 and pUC19 containing specific guide RNA were co-transfected into 293T cells. Single clone of 293T was selected and cultured. Cells were harvested to extract genomic DNA and the DNA was followed by Sanger sequencing and DNAMAN alignment analysis. The sequence information of guide RNAs is provided in Supplementary Table S1 .
Immunofluorescence
Cells grown on coverslips were washed with 1× PBS and fixed in 4% paraformaldehyde for 10 min at room temperature. For FUrd labeling, cells were labeled with 2 mM of FUrd for 5 or 15 min before fixation. After washing three times with 1× PBS (5 min each), cells were permeabilized with 0.5% Triton X-100 for 15 min. Then, cells were washed with PBS for three times (5 min each) and were blocked with 1% BSA in 1× PBS (w/v) for 30 min at room temperature. After washing three times with PBS (5 min each), cells were incubated with primary antibodies diluted in PBST (1× PBS + 0.1% Tween-20) at 4°C overnight. After incubation, cells were washed with PBST (1× PBS + 0.1% Triton X-100) for four times. Then cells were incubated with appropriate secondary antibodies (dilution at 1:400, Invitrogen) for 2 h, washed with 0.1% PBST (Triton X-100) and stained with 2 ng/μl of DAPI for 5 min. The coverslips were sealed and the images were recorded with immunofluorescent microscope. The obtained FUrd signals were quantified with Image J software (National Institutes of Health). For immunofluorescence of endogenous Merm1, we used antibodies from Abcam (ab97911) at a concentration of 20 μg/ml. For immunofluorescence of GFP-tagged or HA-tagged Merm1, fluorescent signals were observed under the spinning-disk confocal laser scanning microscope (Nikon) and analyzed with Volocity 6.3 (PerkinElmer).
ChIP and real-time quantitative PCR
ChIP assays were performed as described (Zhou et al., 2002) . Cross-linked chromatin was sonicated to yield fragments of 400−500 base pairs (bp). Then, the chromatin was pre-cleared, 10% input were reserved and the rest were incubated with respective antibodies. Immunoprecipitated proteins were captured with protein A/G Sepharose beads. After reversal of the crosslinking with the existence of RNase A and digestion of proteins with proteinase K, the DNA was purified by phenol-chloroform extraction or chelex-100 resin and amplified by real-time and quantitative PCR (RT-qPCR). The RT-qPCR was run on Light Cycler (Roche) with 2× SYBR Premix Ex Taq (RR420A, Takara). The conditions were set up according to the tutorial manual provided by the manufacturer. The PCR results were acquired and analyzed by normalization to the 10% input. The ChIP primers used in this study are listed in Supplementary Table S2 .
Co-immunoprecipitation and western blotting assays
To prepare nuclear extract, nuclei were lysed in IP buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100) for 30 min at 4°C and cleared by centrifugation (16000 g, 15 min, 4°C). To prepare whole-cell extract, cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl and add 1 mM PMSF before use) for 1 min and the suspension was diluted 10 times with RIPA buffer without detergent, after incubation for 30 min at 4°C, the lysate was cleared by centrifugation (16000 g, 15 min, 4°C). Then, the lysate was reserved for 10% input and the rest were incubated with respective antibodies at 4°C overnight. Then the protein A/G beads were added to capture the proteins. After washing four times with IP buffer (for nuclear extract) or 0.1× RIPA buffer (for whole-cell extract), the beads carried immunoprecipitated proteins were boiled with 2× SDS loading buffer (80 mM Tris, pH 6.8, 10% glycerol, 2% SDS, 20% β-mercaptoethanol) and centrifuged at 12000 g for 5 min at room temperature. The supernatant and the input were analyzed by western blotting. The protein was subject to SDS-PAGE, transferred to nitrocellulose membrane and incubated with primary antibodies of interest at 4°C overnight. Primary antibodies used were mentioned above. The protein blots were then washed three times in PBST (1× PBS + 0.1% Tween-20) and incubated with diluted secondary antibodies for 2 h at room temperature. And then the blots were washed three times with PBST before visualized under odyssey infrared imaging system (Odyssey, LI-COR).
DNA methylation assays
To monitor CpG methylation, genomic DNA or ChIP-enriched DNA was treated with sodium bisulfite using EpiTect Bisulfite Kit (Qiagen). Briefly, the genomic DNA was subject to bisulfite conversion reaction. The converted DNA was then purified and amplified by PCR with specific primers. The amplicons were electrophoresed by agarose gel and the purified amplicons were ligated into the pEasy-T5 vector. The recombinant pEasy-T5 constructs were transduced into competent Escherichia coli, which were plated and incubated at 37°C. At least 15 independent colonies of the E. coli were selected and sequenced. The sequencing results were analyzed by BiQ analyzer (Max Planck Institut Informatik). The primer information is provided in Supplementary Table S2 .
In vitro DNA methyltransferase activity assays For DNA methyltransferase activity assays, 0.1 μg purified Histagged Dnmt3a or Dnmt3b was incubated with 0−0.2 μg purified GST-tagged Merm1 or His-tagged Dnmt3L at 37°C for 30 min in 10 μl buffer containing 20 mM Hepes, pH 7.5, 50 mM NaCl, 0.5 mg/ml BSA, 0.5 μCi tritiated SAM ( 3 H-S-adenosyl methionine, PerkinElmer), and 100 ng substrate DNA. After the reaction, DNA was recovered and counted in a scintillation counter. Sequence of the substrate DNA is 5′-GATCGCCGATGCGCGAATCGCGATCGAT GCGAT-3′. In addition, quantification of DNA methyltransferase activity was also performed using the EpiQuik DNA Methyltransferase Activity/Inhibition Assay Kit (Epigentek).
Methylated DNA immunoprecipitation and next-generation sequencing
MeDIP DNA libraries were prepared using the NEBNext DNA Library Prep Master Mix Set for Illumina (E6040, NEB). Briefly, fragmented DNA was end repaired and ligated with adapter. After size selection and purification using AMPure XP Beads (A6380, Beckman), the recovered DNA was denatured and incubated with the specific antibody against 5mC. Then, the immunoprecipitated fragments were captured with protein A/G agarose beads. After digestion of proteins with proteinase K, the DNA fragments were extracted and amplified by adaptor-mediated PCR. Libraries were sequenced using the Illumina HiSeq 2000 sequencing platform. The sequencing reads were aligned to mm9 using bowtie2 under the default parameters, then PCR duplicated reads were removed by Picard (MarkDuplicates). Samtools was used to select properly mapped reads (samtools view -Sb -h -f 2). Finally, peaks were detected by macs (-nomodel -nolambda -w -space = 30).
ChIP-Seq
Samples were processed for sequencing using NEBNext DNA Library Prep Master Mix Set for Illumina (E6040, NEB). In brief, ChIP-enriched DNA fragments were end repaired and ligated with adapter. After size selection using AMPure XP Beads, the library was amplified by adaptor-mediated PCR. Libraries were sequenced using the Illumina HiSeq 2000 sequencing platform. The alignment step was the same as MeDIP-seq, but the peaks calling were using masc under the default parameters (Landt et al., 2012) .
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
